Introduction {#s1}
============

Coronary artery disease (CHD) is the most common form of cardiovascular disease which remains the leading cause of mortality and morbidity worldwide [@pone.0045641-Global1]. CHD accounts for 7.3 million death in 2008 [@pone.0045641-Causes1]. CHD is an extremely complex and multifactorial disease, which is attributed to multiple genetic and environment factors and their interactions.

It is well known that atherosclerosis is the underlying pathology of CHD through a slowly progressing lesion formation and luminal narrowing of arteries [@pone.0045641-Weber1]. Growing evidence has suggested that inflammation plays an important role in the initiation and progression of atherosclerosis, which is recognized as a progressive inflammatory disorder [@pone.0045641-Weber1]--[@pone.0045641-Libby1]. The adventitial inflammation of advanced plaques can be attributed to the release of some enzymes, cytokines and chemokines [@pone.0045641-Weber1], [@pone.0045641-Buffon1]. Interleukin-1 (IL-1) family is a critical mediator of inflammatory response with two agonists (IL-1α and IL-1β) and one antagonist (Interleukin-1 Receptor antagonist: IL-1Ra) [@pone.0045641-Smith1]. The *IL-1* gene cluster, located within 430 kb region on chromosome 2 (2q13-21), contains *IL-1A*, *IL-1B* and *IL-1RN* (encoding IL-1α, IL-1β and IL-1Ra, respectively) genes [@pone.0045641-Dinarello1]. Three single nucleotide polymorphisms (SNPs) of the *IL-1* gene cluster have been most frequently studied in relation to CHD risk: one SNP at promoter position −511 C/T and another one in exon 5 at position +3954 C/T of the *IL-1B* gene and a variable number of tandem repeats (VNTR) of 86 bp polymorphism in intron 2 of *IL-1RN* gene [@pone.0045641-ElOmar1], [@pone.0045641-Vamvakopoulos1], which generates a short allele with two repeats (*IL-1RN\*2*) and long alleles with three to six repeats (*IL-1RN L*) [@pone.0045641-Vamvakopoulos1].

To date, a great number of studies regarding the associations between *IL-1* gene cluster polymorphisms and CHD risk have been published. However, results have been inconsistent [@pone.0045641-Francis1]--[@pone.0045641-Zeybek1]. Chen et al performed a meta-analysis in Chinese to investigate the associations between *IL-1* gene polymorphisms and CHD in 2000 [@pone.0045641-Chen1] and only seven papers were included in that meta-analysis. In addition, it did not investigate the relationship between *IL-1B+3954* polymorphism and CHD risk. Therefore, in this study, we performed a meta-analysis to further clarify the associations between *IL-1B-511*, *IL-1B+3954* and *IL-1RN VNTR* polymorphisms and CHD risk.

Materials and Methods {#s2}
=====================

Literature and search strategy {#s2a}
------------------------------

The PubMed and Embase database searches were performed to identify all eligible articles. The search strategy involved the use of combination of the following key words: (Interleukin-1 or IL-1) and (variant or variation or polymorphism) and (coronary disease or coronary heart disease or coronary artery disease or myocardial infarct or ischemic heart disease or CHD or IHD or MI or cardiovascular disease or heart disease OR angina). The publication languages were restricted to English and Chinese. The reference lists of retrieved articles were hand-searched. If more than one article was published using the same study data, only the study with the largest sample size was included. The literature search was updated on April 20, 2012.

Inclusion criteria and data extraction {#s2b}
--------------------------------------

Studies were included in the analysis if they met the following inclusion criteria: (1) a case-control or cohort study; (2) evaluating the associations of IL-1 genetic polymorphisms (include *IL-1B-511*, *IL-1B+3954* or *IL-1RN VNTR*) with CHD risk; and (3) providing sufficient data for calculation of an odds ratio (OR) with 95% confidence interval (CI). The following information was extracted from each study: (1) name of first author; (2) year of publication; (3) country of origin; (4) ethnicity of the study population; (5) source of controls (population- or hospital-based); (6) sample size of cases and controls; (7) cardiovascular end point; (8) gender distribution and mean age of subjects in cases and controls; (9) genotype distributions in cases and controls; and (10) *p* value for the test of Hardy--Weinberg equilibrium (HWE) in controls. Two authors independently assessed the articles for compliance with the inclusion criteria, and disagreement was followed by discussion until consensus was reached.

Statistical analysis {#s2c}
--------------------

The associations between *IL-1* genetic polymorphisms and CHD risk were estimated by calculating pooled ORs and 95%CI under multiplicative, co-dominant, dominant, and recessive genetic models, respectively. The significance of pooled ORs was determined by *Z* tests (*p*\<0.05 was considered statistically significant). A Q test was performed to evaluate whether the heterogeneity existed. A random- (DerSimonian-Laird method) [@pone.0045641-DerSimonian1] or fixed- (Mantel-Haenszel method) [@pone.0045641-Mantel1] effects model was used to calculate the pooled ORs in the presence (*p*\< = 0.10) or absence (*p*\>0.10) of heterogeneity. Meta-regression was performed to explore the potentially important sources of between-study heterogeneity. Subgroup analyses based on ethnicity, cardiovascular end point, source of controls and sample size (n\<400 vs.n≥400) were also performed. Sensitivity analysis, removing one study at a time, was performed to evaluate the stability of the results. Begg\'s funnel plot, a scatter plot of effect against study size, was generated as a visual aid to detect bias or systematic heterogeneity [@pone.0045641-Begg1]. Publication bias was assessed by Egger\'s test [@pone.0045641-Egger1] (*p*\<0.05 was considered statistically significant). Data analysis was performed using STATA version 11 (StataCorp LP, College Station, TX, USA).

Results {#s3}
=======

Characteristics of the studies {#s3a}
------------------------------

A total of 530 potentially relevant papers were identified based on the search strategy. Of these, 500 papers were excluded because of obvious irrelevance by reading their titles and abstracts. After the full texts were read, four papers were excluded because they didn\'t provide sufficient data for calculation of OR with 95% CI [@pone.0045641-Hackett1]--[@pone.0045641-Kornman1]; two papers were excluded because of examining the associations of other genetic polymorphisms rather than the three polymorphisms studied in our analysis [@pone.0045641-vanMinkelen1]--[@pone.0045641-Banerjee1]; another paper was excluded because it was family-based study [@pone.0045641-Brown1]. In addition, two reviews [@pone.0045641-Chen1], [@pone.0045641-Auer1] and two comments [@pone.0045641-Keavney1], [@pone.0045641-Momiyama2] were excluded with the exception of the one by Iacoviello et al [@pone.0045641-Iacoviello1], which provided a new study concerning the association of *IL-1RN VNTR* polymorphism and CHD. Furthermore, more than one study were included in each of the two papers by Francis et al [@pone.0045641-Francis1] and Rios et al [@pone.0045641-Rios1], respectively, and they were considered as separate studies in the following data analysis. Thus, thirteen studies [@pone.0045641-Francis1], [@pone.0045641-Vohnout1]--[@pone.0045641-Zhang1], [@pone.0045641-Arman1]--[@pone.0045641-Zee2], [@pone.0045641-Rios1], [@pone.0045641-Coker1] on *IL-1B-511* polymorphism, nine studies [@pone.0045641-Iacoviello2], [@pone.0045641-Arman1]--[@pone.0045641-Zhu1], [@pone.0045641-Coker1], [@pone.0045641-Zeybek1] on *IL-1B+3954* polymorphism, twelve studies [@pone.0045641-Francis1]--[@pone.0045641-Vohnout1], [@pone.0045641-Kariz1]--[@pone.0045641-Soylu1], [@pone.0045641-Fragoso1], [@pone.0045641-Coker1], [@pone.0045641-Gorcy1] on *IL-1RN VNTR* polymorphism were included in the final meta-analyses. A flow chart demonstrating the inclusion/exclusion of studies was displayed as [Figure 1](#pone-0045641-g001){ref-type="fig"}. The characteristics of the included studies were listed in [Table 1](#pone-0045641-t001){ref-type="table"}.

![Selection of articles for inclusion in meta-analysis.](pone.0045641.g001){#pone-0045641-g001}
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###### Characteristics of studies included in the meta-analysis.

![](pone.0045641.t001){#pone-0045641-t001-1}

  Study                         Year   Country    Ethnicity   Source of controls   Sample size (case/control)   End point   Mean age in case/control, (years)   \% of male (case/control)   Genotype distribution   *P* ~HWE~ [a](#nt103){ref-type="table-fn"}                                     
  ---------------------------- ------ ---------- ----------- -------------------- ---------------------------- ----------- ----------------------------------- --------------------------- ----------------------- -------------------------------------------- -------- -- -------- ----- ------- ---------
  *IL-1B-511* polymorphism                                                                                                                                                                                                                                                                         
  Francis^11^                   1999      UK      Caucasian           PB                    425/130                CHD                  58.9/58.9                        77.6/43                   574^b^                                                        276^c^      193^b^         67^c^    ≥0.05
  Francis^11^                   1999      UK      Caucasian           PB                    248/102                CHD                  61.1/57.4                        76.5/36                   335^b^                                                        161^c^      138^b^         66^c^    ≥0.05
  Vohnout^14^                   2003   Slovakia   Caucasian           HB                    335/205                CHD                  59.5/56.6                       83.6/46.8                    151                               152                         32          90     89     26      0.587
  Licastro^15^                  2004    Italy     Caucasian           PB                    139/198                MI                     65/57                          100/100                     65                                 60                         14          46     65     11      0.075
  Iacoviello^16^                2005    Italy     Caucasian           PB                    406/419                MI                     41/40                           85/85                      195                               180                         31         174     187    58      0.495
  Zhang^17^                     2006    China       Asian             PB                    127/152                CHD                    52/44                         66.9/64.5                    25                                 79                         23          38     92     22      0.006
  Arman^19^                     2008    Turkey    Caucasian           HB                    257/170                CHD                  58.0/51.4                       72.4/53.5                    75                                130                         52          51     74     45      0.094
  Geismar^20^                   2008   Denmark    Caucasian           HB                     96/123                CHD                  63.8/61.8                       69.1/62.5                    43                                 42                         11          60     50     13      0.595
  Soylu^21^                     2008    Turkey    Caucasian           HB                    264/117                ACS                  58.3/52.4                       73.1/48.7                    81                                128                         55          28     58     31      0.932
  Zee^22^                       2008     USA      Caucasian           PB                    341/341                MI                   60.2/60.1                        100/100                     148                               154                         39         164     137    40      0.172
  Rios^26^                      2010    Brazil     African            HB                    138/115                CHD                  55.7/51.8                       64.5/43.5                    42                                 64                         32          19     67     29      0.062
  Rios^26^                      2010    Brazil    Caucasian           HB                    276/138                CHD                  55.7/53.0                       66.7/45.6                    80                                130                         66          47     69     22      0.69
  Coker^27^                     2011    Turkey    Caucasian           HB                    167/235                MI                   53.4/53.9                         70/43                      59                                 72                         36          77     113    45      0.758
  *IL-1B+3954* polymorphism                                                                                                                                                                                                                                                                        
  Iacoviello^16^                2005    Italy     Caucasian           PB                    406/419                MI                     \<50                             NA                        244                               140                         14         258     130    14      0.63
  Arman^19^                     2008    Turkey    Caucasian           HB                    257/170                CHD                  58.0/51.4                       72.4/53.5                    151                                91                         15          93     68      9      0.446
  Geismar^20^                   2008   Denmark    Caucasian           HB                     96/123                CHD                  63.8/61.8                       69.1/62.5                    51                                 38                         7           67     45     11      0.393
  Soylu^21^                     2008    Turkey    Caucasian           HB                    264/117                CHD                  58.3/52.4                       73.1/48.7                    157                                93                         14          69     41      7      0.783
  Zee^22^                       2008     USA      Caucasian           PB                    341/341                MI                   60.2/60.1                        100/100                     188                               130                         23         198     123    20      0.877
  Stein^23^                     2009   Germany    Caucasian           HB                     54/50                 AMI                  50.8/51.7                        92.6/94                    48^b^                                                        24^c^       48^b^          21^c^    ≥0.05
  Zhu^24^                       2009    China       Asian             HB                    100/144                CHD                  61.5/60.3                        67/67.4                     97                                 3                          0          142      2      0      0.933
  Coker^27^                     2011    Turkey    Caucasian           HB                    167/235                MI                   53.4/53.9                         70/43                      86                                 68                         13         136     84     15      0.677
  Zeybek^29^                    2011    Turkey    Caucasian           PB                    143/213                MI                   58.9/56.4                       68.5/39.9                    79                                 46                         18         140     54     19     \<0.001
  *IL-1RN VNTR* polymorphism                                                                                                                                                                                                                                                                       
  Francis^11^                   1999      UK      Caucasian           PB                    425/130                CHD                  58.9/58.9                        77.6/43                   628^b^                                                        222^c^      201^b^         59^c^    ≥0.05
  Francis^11^                   1999      UK      Caucasian           PB                    248/102                CHD                  61.1/57.4                        76.5/36                   356^b^                                                        140^c^      171^b^         33^c^    ≥0.05
  Iacoviello^12^                2000    Italy     Caucasian           PB                    158/153                AMI                    \<50                            81.6/                    237^b^                                                        79^c^       229^b^         77^c^    ≥0.05
  Zee^13^                       2001     USA      Caucasian           PB                    385/385                MI                   59.6/59.5                           M                        219                               140                         26         218     137    30      0.199
  Vohnout^14^                   2003   Slovakia   Caucasian           HB                    335/205                CHD                  59.5/56.6                       83.6/46.8                    200                               114                         21         127     68     20      0.02
  Kariz^18^                     2007   Slovenia   Caucasian           PB                    151/223                MI                   59.2/66.5                       65.6/45.7                    87                                 49                         15         134     75     14      0.428
  Arman^19^                     2008    Turkey    Caucasian           HB                    257/170                CHD                  58.0/51.4                       72.4/53.5                    150                                84                         23         105     56      9      0.67
  Geismar^20^                   2008   Denmark    Caucasian           HB                     96/123                CHD                  63.8/61.8                       69.1/62.5                    59                                 32                         4           68     40     15      0.027
  Soylu^21^                     2008    Turkey    Caucasian           HB                    264/117                CHD                  58.3/52.4                       73.1/48.7                    149                                96                         19          59     45     13      0.33
  Fragoso^25^                   2010    Mexico      Mixed             PB                    300/248                ACS                    59/56                           79/79                      177                                90                         33         113     97     38      0.029
  Coker^27^                     2011    Turkey    Caucasian           HB                    167/235                MI                   53.4/53.9                         70/43                      88                                 52                         27         124     77     34     \<0.001
  Goracy^28^                    2011    Poland    Caucasian           HB                    201/117                CHD                  57.3/55.2                       82.1/59.0                    93                                 86                         22          57     48     12      0.689

*Notes* For *IL-1B-511* and *IL-1B+3954* polymorphisms, 11 = CC, 12 = CT, 22 = TT; for *IL-1RN VNTR* polymorphism, 11 = L/L, 12 = \*2/L, 22 = \*2/\*2;

PB, Population-based; HB, Hospital-based; NA, not available;

, *p* value for Hardy-Weinberg equilibrium in controls; ^b,^ allele represented by 1; ^c,^ allele represented by 2;

CHD = coronary artery disease; ACS = acute coronary syndrome; MI = myocardial infarction.

Quantitative data synthesis {#s3b}
---------------------------

For *IL-1B-511* polymorphism, a total of 3,219 cases and 2,445 controls were identified. Overall, the results showed no significant association between this polymorphism and CHD risk (T vs. C: OR = 0.98, 95%CI 0.87--1.09; TT vs. CC : OR = 0.87, 95%CI 0.67--1.13; TC vs. CC: OR = 0.96, 95%CI 0.84--1.09; TT+TC vs. CC: OR = 0.93, 95%CI 0.79--1.10; TT vs. TC+CC: OR = 0.91, 95%CI 0.74--1.12) ([Table 2](#pone-0045641-t002){ref-type="table"}, [Figure 2](#pone-0045641-g002){ref-type="fig"}). In the subgroup analysis, there was no statistically significant association in each subgroup by ethnicity, cardiovascular end point, source of controls and sample size under all genetic models except for the association for Africans under co-dominant and dominant models ([Table 2](#pone-0045641-t002){ref-type="table"}). However, the positive result of subgroup analysis by ethnicity was not reliable for Africans because only one study was performed in African patients.

![Meta-analysis of the association between *IL-1B -511* polymorphism and CHD risk (T vs. C).](pone.0045641.g002){#pone-0045641-g002}

10.1371/journal.pone.0045641.t002

###### Summary ORs and 95%CIs of the association between *IL-1B -511* polymorphism and CHD risk.

![](pone.0045641.t002){#pone-0045641-t002-2}

  Contrasts             No. of studies   T vs. C   No. of studies   TT vs. CC   TC vs. CC   TT+TC vs. CC   TT vs. TC+CC                                                                                      
  -------------------- ---------------- --------- ---------------- ----------- ----------- -------------- -------------- ------- ------ ------------ ------- ------ ------------ ------- ------ ------------ -------
  All                         13          0.98       0.87--1.09       0.020        11           0.87        0.67--1.13    0.039   0.96   0.84--1.09   0.125   0.93   0.79--1.10   0.069   0.91   0.74--1.12   0.100
  Studies in HWE              12          0.96       0.85--1.08       0.022        10           0.83        0.64--1.08    0.058   0.94   0.82--1.08   0.119   0.91   0.76--1.08   0.078   0.87   0.74--1.03   0.105
  Ethnicity                                                                                                                                                                                                  
  Caucasian                   11          0.98       0.87--1.11       0.031         9           0.87        0.66--1.14    0.069   0.98   0.85--1.12   0.422   0.95   0.83--1.07   0.255   0.88   0.69--1.13   0.069
  Asian                       1           1.20       0.86--1.67        \-           1           1.59        0.73--3.44     \-     1.31   0.73--2.35    \-     1.36   0.77--2.41    \-     1.31   0.69--2.48    \-
  African                     1           0.73       0.51--1.03        \-           1           0.50        0.24--1.05     \-     0.43   0.23--0.82    \-     0.45   0.25--0.83    \-     0.90   0.50--1.59    \-
  End point                                                                                                                                                                                                  
  CHD                         9           1.01       0.87--1.17       0.050         7           0.91        0.64--1.29    0.065   0.99   0.82--1.19   0.150   0.96   0.75--1.22   0.093   0.93   0.76--1.15   0.183
  MI                          4           0.91       0.75--1.11       0.077         4           0.82        0.53--1.26    0.078   0.93   0.78--1.12   0.137   0.90   0.76--1.07   0.109   0.87   0.58--1.31   0.075
  Source of controls                                                                                                                                                                                         
  HB                          7           0.95       0.84--1.06       0.156         7           0.88        0.70--1.11    0.123   0.93   0.78--1.12   0.184   0.93   0.78--1.10   0.152   0.94   0.76--1.15   0.203
  PB                          6           1.02       0.83--1.24       0.013         4           0.89        0.52--1.53    0.030   0.98   0.73--1.31   0.100   0.95   0.70--1.30   0.049   0.88   0.57--1.31   0.070
  Sample size                                                                                                                                                                                                
  Small                       6           0.92       0.80--1.06       0.249         5           0.82        0.59--1.15    0.192   0.81   0.56--1.17   0.073   0.82   0.57--1.18   0.057   0.95   0.72--1.27   0.679
  Large                       7           1.01       0.86--1.19       0.011         6           0.89        0.63--1.27    0.024   1.02   0.88--1.19   0.517   0.98   0.85--1.13   0.264   0.88   0.63--1.22   0.020

*Notes* OR, odds ratio; CI, confidence interval; *P* ~H,~ *P* value based on Q test for between-study heterogeneity; HWE =  Hardy--Weinberg equilibrium;

CHD = coronary artery disease; ACS = acute coronary syndrome; MI = myocardial infarction; PB, Population-based; HB, Hospital-based.

For *IL-1B+3954* polymorphism, six studies comprised 1,828 cases and 1,818 controls were identified. The overall result suggested no statistically significant association of this polymorphism with CHD susceptibility (T vs. C: OR = 1.06, 95%CI 0.95--1.19; TT vs. CC : OR = 1.18, 95%CI 0.87--1.58; TC vs. CC: OR = 1.12, 95%CI 0.96--1.30; TT+TC vs. CC: OR = 1.13, 95%CI 0.98--1.30; TT vs. TC+CC: OR = 1.12, 95%CI 0.84--1.50) ([Table 3](#pone-0045641-t003){ref-type="table"}, [Figure 3](#pone-0045641-g003){ref-type="fig"}). In the subgroup analysis by ethnicity, cardiovascular end point, source of controls and sample size, no significant association was observed in each subgroup under all genetic models ([Table 3](#pone-0045641-t003){ref-type="table"}).

![Meta-analysis of the association between *IL-1B +3954* polymorphism and CHD risk (T vs. C).](pone.0045641.g003){#pone-0045641-g003}
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###### Summary ORs and 95%CIs of the association between *IL-1B +3954* polymorphism and CHD risk.

![](pone.0045641.t003){#pone-0045641-t003-3}

  Contrasts             No. of studies   T vs. C   No. of studies   TT vs. CC   TC vs. CC   TT+TC vs. CC   TT vs. TC+CC                                                                                        
  -------------------- ---------------- --------- ---------------- ----------- ----------- -------------- -------------- ------- ------ ------------- ------- ------ ------------- ------- ------ ------------ -------
  All                         9           1.06       0.95--1.19       0.576         8           1.18        0.87--1.58    0.910   1.12   0.96--1.30    0.678   1.13   0.98--1.30    0.592   1.12   0.84--1.50   0.962
  Studies in HWE              8           1.02       0.90--1.15       0.892         7           1.09        0.78--1.51    0.969   1.08   0.93--1.27    0.783   1.09   0.93--1.26    0.781   1.06   0.77--1.46   0.981
  Ethnicity                                                                                                                                                                                                    
  Caucasian                   8           1.06       0.94--1.18       0.537         7           1.18        0.87--1.58    0.910   1.11   0.96--1.29    0.635   1.12   0.97--1.29    0.540   1.12   0.84--1.50   0.962
  Asian                       1           2.18      0.36--13.15        \-           1            \-             \-         \-     2.20   0.36--13.39    \-     2.20   0.36--13.39    \-      \-        \-        \-
  End point                                                                                                                                                                                                    
  CHD                         4           0.96       0.78--1.17       0.817         4           0.92        0.54--1.58    0.949   0.96   0.73--1.25    0.655   0.95   0.74--1.23    0.725   0.94   0.55--1.59   0.876
  MI                          5           1.11       0.97--1.27       0.354         4           1.31        0.92--1.87    0.836   1.20   1.00--1.43    0.728   1.21   1.03--1.44    0.614   1.21   0.86--1.72   0.907
  Source of controls                                                                                                                                                                                           
  HB                          6           0.95       0.80--1.12       0.923         4           1.04        0.67--1.63    0.857   1.04   0.83--1.30    0.568   1.04   0.84--1.29    0.570   1.02   0.66--1.59   0.895
  PB                          3           1.16       1.00--1.36       0.357         4           1.29        0.87--1.93    0.656   1.18   0.97--1.44    0.550   1.20   0.99--1.45    0.430   1.21   0.82--1.79   0.760
  Sample size                                                                                                                                                                                                  
  Small                       5           1.15       0.94--1.41       0.456         4           1.19        0.73--1.95    0.411   1.21   0.91--1.60    0.574   1.21   0.92--1.57    0.422   1.10   0.68--1.79   0.520
  Large                       4           1.02       0.89--1.17       0.563         4           1.17        0.80--1.70    0.956   1.09   0.91--1.29    0.479   1.10   0.93--1.30    0.494   1.13   0.78--1.63   0.986

*Notes* OR, odds ratio; CI, confidence interval; *P* ~H,~ *P* value based on Q test for between-study heterogeneity; HWE =  Hardy--Weinberg equilibrium;

CHD = coronary artery disease; ACS = acute coronary syndrome; MI = myocardial infarction; PB, Population-based; HB, Hospital-based.

For *IL-1RN VNTR* polymorphism, A total of 2,987 cases and 2,208 controls were identified. The overall result suggested no statistically significant association of this polymorphism with CHD risk (\*2 vs. L: OR = 1.00, 95%CI 0.85--1.17; \*2/\*2 vs. L/L: OR = 0.86, 95%CI 0.63--1.18; \*2/L vs. L/L: OR = 0.93, 95%CI 0.81--1.07; \*2/\*2 + \*2/L vs. L/L: OR = 0.92, 95%CI 0.81--1.04; \*2/\*2 vs. \*2/L +\*2/L: OR = 0.88, 95%CI 0.81--1.04) ([Table 4](#pone-0045641-t004){ref-type="table"}, [Figure 4](#pone-0045641-g004){ref-type="fig"}). In the further subgroup analyses based on ethnicity, there was no statistically significant association in all genetic models except for the association in Mixed population under multiplicative, co-dominant and dominant models ([Table 4](#pone-0045641-t004){ref-type="table"}). However the positive association was not reliable because it derived from one study. Subgroup analyses based on cardiovascular end point showed that the effect sizes of *IL-1RN VNTR* with ACS risk were statistically significant under multiplicative, co-dominant and dominant models ([Table 4](#pone-0045641-t004){ref-type="table"}), which also should be interpreted with caution since only one study was included under these three genetic models.

![Meta-analysis of the association between *IL-1RN VNTR* polymorphism and CHD risk (\*2 vs. L).](pone.0045641.g004){#pone-0045641-g004}
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###### Summary ORs and 95%CIs of the association between *IL-1RN VNTR* polymorphism and CHD risk.

![](pone.0045641.t004){#pone-0045641-t004-4}

  Contrasts             No. of studies   \*2 vs. L   No. of studies   \*2/\*2 vs. L/L   \*2/L vs. L/L   \*2/\*2 + \*2/L vs. L/L   \*2/\*2 vs. \*2/L +\*2/L                                                                                      
  -------------------- ---------------- ----------- ---------------- ----------------- --------------- ------------------------- -------------------------- ------- ------ ------------ ------- ------ ------------ ------- ------ ------------ -------
  All                         12           1.00        0.85--1.17          0.001              9                  0.86                    0.63--1.18          0.071   0.93   0.81--1.07   0.476   0.92   0.81--1.04   0.194   0.88   0.71--1.10   0.132
  Studies in HWE              8            1.12        0.94--1.32          0.043              5                  1.06                    0.78--1.46          0.215   1.00   0.84--1.20   0.950   1.02   0.86--1.21   0.727   1.06   0.78--1.44   0.246
  Ethnicity                                                                                                                                                                                                                                     
  Caucasian                   11           1.04        0.90--1.20          0.020              8                  0.94                    0.73--1.20          0.127   1.00   0.86--1.16   0.996   0.99   0.86--1.14   0.875   0.94   0.74--1.19   0.132
  Mixed                       1            0.66        0.51--0.85           \-                1                   0.5                    0.33--0.94           \-     0.59   0.41--0.86    \-     0.58   0.41--0.82    \-     0.68   0.41--1.13    \-
  End point                                                                                                                                                                                                                                     
  CHD                         7            1.05        0.82--1.33          0.003              5                  0.79                    0.47--1.33          0.087   1.00   0.82--1.23   0.927   0.96   0.80--1.16   0.602   0.81   0.58--1.13   0.101
  MI                          4            1.03        0.89--1.19          0.811              3                  1.09                    0.76--1.56          0.411   1.00   0.80--1.24   0.970   1.02   0.83--1.25   0.905   1.10   0.78--1.55   0.386
  ACS                         2            0.79        0.53--1.18          0.07               1                  0.55                    0.33--0.94           \-     0.59   0.41--0.86   0.242    \-    0.41--0.82    \-     0.68   0.41--1.13    \-
  Source of controls                                                                                                                                                                                                                            
  HB                          7            0.97        0.86--1.10          0.176              6                  0.88                    0.66--1.19          0.108   1.00   0.83--1.20   0.968   0.97   0.82--1.15   0.735   0.89   0.67--1.18   0.116
  PB                          5            1.06        0.77--1.47          0.000              3                  0.87                    0.49--1.55          0.071   0.85   0.59--1.21   0.063   0.86   0.58--1.15   0.025   0.88   0.63--1.22   0.165
  Sample size                                                                                                                                                                                                                                   
  Small                       6            1.05        0.79--1.39          0.004              4                  0.82                    0.42--1.58          0.065   0.97   0.76--1.23   0.886   0.94   0.75--1.18   0.505   0.83   0.45--1.55   0.076
  Large                       6            0.95        0.79--1.15          0.024              5                  0.85                    0.65--1.11          0.124   0.92   0.78--1.08   0.146   0.91   0.72--1.15   0.068   0.89   0.69--1.16   0.231

*Notes* OR, odds ratio; CI, confidence interval; *P* ~H,~ *P* value based on Q test for between-study heterogeneity; HWE =  Hardy--Weinberg equilibrium;

CHD = coronary artery disease; ACS = acute coronary syndrome; MI = myocardial infarction; PB, Population-based; HB, Hospital-based.

Source of heterogeneity {#s3c}
-----------------------

As shown in [Table 2](#pone-0045641-t002){ref-type="table"}, [3](#pone-0045641-t003){ref-type="table"}, [4](#pone-0045641-t004){ref-type="table"}, evidence for heterogeneity (*p*\<0.10) between studies was found under the multiplicative, co-dominant (TT vs. CC) and dominant genetic models for *IL-1B-511*, under multiplicative and co-dominant (\*2/\*2 vs. L/L) genetic models for *IL-1RN VNTR* polymorphism, respectively. No evidence for heterogeneity between studies was found for *IL-1B-511* under the co-dominant (TC vs. CC) and recessive genetic models, for *IL-1RN VNTR* under co-dominant (\*2/L vs. L/L), dominant and recessive genetic models and for *IL-1B+3954* polymorphism under all the genetic models.

The meta-regression was conducted with the introduction of covariates including ethnicity, publication year, gender, age, sample size, source of controls and cardiovascular end point for the above mentioned polymorphisms. However, no covariate was identified as a potential source of between-study heterogeneity for any comparison.

Sensitivity analysis {#s3d}
--------------------

Sensitivity analysis was performed by excluding one study at a time (data not shown) and the non-association results did not substantially alter.

Potential publication bias {#s3e}
--------------------------

Using Egger\'s test, no publication bias could be detected for studies published on *IL-1B-511* polymorphism (T vs. C: *p* = 0.388; TT vs. CC: 0.816; TC vs. CC: *p* = 0.592; TT+TC vs. CC: *p* = 0.068; TT vs. TC+CC: *p* = 0.496); IL-1B+3954 polymorphism (T vs. C: *p* = 0.461; TT vs. CC: *p* = 0.231; TC vs. CC: *p* = 0.427; TT+TC vs. CC: *p* = 0.776; TT vs. TC+CC: *p* = 0.691) and *IL-1RN VNTR* polymorphism (\*2 vs. L: *p* = 0.295; \*2/\*2 vs. L/L: *p* = 0.172; \*2/L vs. L/L: *p* = 0.152; \*2/\*2 + \*2/L vs. L/L: *p* = 0.106; for \*2/\*2 vs. \*2/L +\*2/L: *p* = 0.855).

Discussion {#s4}
==========

Cytokines of the IL-1 family were believed to influence the inflammatory response and inflammation-related atherosclerosis, and these in turn lead to CHD and other cardiovascular diseases such as stroke [@pone.0045641-Weber1], [@pone.0045641-Sims1], [@pone.0045641-Nicklin1]. Because of the effects of cytokines on inflammatory response, a series of studies have focused on the contribution of polymorphisms within the IL-1 cluster genes to the CHD risk. However, results have been contradictory. Given the relatively small sample sizes of the included individual studies for detecting the modest genetic effect, we conducted the present meta-analysis, although there were still the limited power of meta-analysis due to size and heterogeneity of studies/patients.

Our results suggested that there was no significant association between the three polymorphisms (*IL-1B-511*, *IL-1B+3954* and *IL-1RN VNTR*) within the *IL-1* gene cluster and CHD risk. One previous meta-analysis also failed to suggest statistically significant associations of *IL-1B-511* and *IL-1RN VNTR* polymorphisms with stroke risk in the overall population, with ORs and 95%CI of 1.22 (0.85--1.87) for TT vs. CC and 1.22 (0.85--1.75) for RN2/RN2 vs. RN1/RN1 [@pone.0045641-Ye1]. In addition, the previous meta-analysis by Chen et al in Chinese showed that *IL-1* gene cluster polymorphisms did not seem to affect CHD risk, with ORs and 95%CI of 1.04 (0.93--1.18) for *IL-1B-511* and 1.01 (0.78--1.17) for *IL-1RN VNTR* under multiplicative models [@pone.0045641-Chen1].

IL-1β, released by macrophages, platelets, and injured endothelium [@pone.0045641-Andreotti1], plays a central role in the inflammatory response and its related atherosclerosis. IL-1β may act on atherosclerosis with different biological functions such as stimulating proliferation of vascular smooth muscle cells and endothelial cells [@pone.0045641-Kim1], [@pone.0045641-Yang1], increasing expression of adhesional molecule from endothelial cells [@pone.0045641-Yang1], modificating the endothelium to promote coagulation and thrombosis [@pone.0045641-Dinarello2], stimulating the synthesis of fatty acid carrier protein by adipose tissue in vitro [@pone.0045641-Memon1], promoting the production of some other pro-inflammatory factors such as IL-6, fibrinogen and C-reactive protein [@pone.0045641-Sims1], [@pone.0045641-Nicklin1]. At the same time, IL-1Ra regulates inflammation by functioning as an endogenous inhibitor of IL-1β and competing for IL-1 receptor. Therefore, the balance between IL-1β and IL-1Ra is thought to contribute to the pathogenesis of atherosclerosis [@pone.0045641-Sims1], [@pone.0045641-Nicklin1]. In addition, some evidence has indicated that elevated levels of IL-1 and IL-1Ra mRNA were observed in atherosclerotic arteries compared with normal arteries [@pone.0045641-Olofsson1]. In addition, T allele of the *IL-1B-511* polymorphism and 2 allele of the *IL-1RN VNTR* polymorphism have been associated with enhanced IL-1b production [@pone.0045641-Santtila1], [@pone.0045641-Hurme1]. Nevertheless, no significant association was found between *IL-1* gene cluster polymorphisms and cardiovascular diseases by meta-analysis.

Considering that CHD is a multifactorial trait and the impact of the inflammatory cytokine on CHD progress may be modulated by age, gender and some other environmental and genetic factors across different ethnicities, the subgroup analysis based on ethnicity was performed, which showed that *IL-1B-511* polymorphism was only associated with CHD in Africans under co-dominant and dominant models, *IL-1RN VNTR* polymorphism associated in Mixed population under multiplicative, co-dominant and dominant models, respectively. However, the results were not very credible due to just one study included in the Africans and Mixed population separately.

Furthermore, the subgroup analysis indicated the positive association of *IL-1RN VNTR* polymorphism with ACS but not with other cardiovascular end point. However, what also needs to be pointed out is that the significant association derived from only one study and thus the result should be interpreted with caution because of the relatively small sample size or multiple testing driving false positive findings.

There are several limitations in the meta-analysis. First, our analysis was primarily based on unadjusted effect estimates and therefore the potential covariates including age, gender and environmental factors such as smoking and levels of HDL-cholesterol, which might influence the effect estimates, were not controlled for. Second, despite of evidence of between-study heterogeneity in some comparisons in our meta-analysis, none of the covariates including ethnicity, publication year, gender, age, sample size, source of controls and cardiovascular end point was identified as a potential source of heterogeneity between studies by meta-regression. Therefore, other unknown confounding factors may help explain the between-study heterogeneity. Third, the possibility of a false negative remains due to the small size of the studies even when combined. Thus, further studies with larger sample size are required to investigate the associations. Fourth, as none of the studies included in this meta-analysis considered the effect of gene-gene/environment interactions involved in the pathogenesis of CHD, this issue could not addressed in our meta-analysis. Fifth, as is known, haplotype analysis might bring out bigger net effects. However, most studies, except for the studies by Zee et al [@pone.0045641-Zee1]and Fragoso et al [@pone.0045641-Fragoso1], did not perform haplotype analyses, which impeded our further analysis. Sixth, it is conceivable, that patients with a higher inflammatory status and a polymorphism in IL1B or IL1RA have stronger association to coronary heart disease than patients without inflammation. Analysis of hsCRP in a subgroup could help to answer this question. Three studies (the study by Iacoviello et al [@pone.0045641-Iacoviello2], Soylu et al [@pone.0045641-Soylu1] and Coker et al [@pone.0045641-Coker1]) provided the data about hsCRP. However, only the study by Iacoviello et al [@pone.0045641-Iacoviello2] provided the hsCRP-adjusted OR with 95% CI; the other two studies by Soylu et al [@pone.0045641-Soylu1] and Coker et al [@pone.0045641-Coker1] only provided the hsCRP levels between cases and controls. Therefore, subgroup analysis of the effect of hsCRP on variant-CHD association can not yet been conducted so far.

In summary, our meta-analyses suggested that *IL-1* gene cluster polymorphisms were not associated with CHD risk. More in depth researches considering gene-environment interactions and haplotype information should be conducted to further investigate these associations between *IL-1* gene cluster polymorphisms and CHD risk.
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